The IL-6R chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo
http://www.100md.com
《神经病学神经外科学杂志》
Original citation: J. Clin. Invest. 115:313–325 (2005). doi:10.1172/JCI200522433
Citation for this corrigendum: J. Clin. Invest. 115:1388 (2005). doi:10.1172/JCI200522433C1
Aysefa Doganci,1 Tatjana Eigenbrod,1 Norbert Krug,2 George T. De Sanctis,3 Michael Hausding,1 Veit J. Erpenbeck,2 El-Bdaoui Haddad,2 Hans A. Lehr,4 Edgar Schmitt,5 Tobias Bopp,5 Karl-J. Kallen,6 Udo Herz,7 Steffen Schmitt,8 Cornelia Luft,1 Olaf Hecht,2 Jens M. Hohlfeld,2 Hiroaki Ito,9 Norihiro Nishimoto,9 Kazuyuki Yoshizaki,10 Tadamitsu Kishimoto,10 Stefan Rose-John,6 Harald Renz,7 Markus F. Neurath,11 Peter R. Galle,11 and Susetta Finotto1
1Laboratory of Cellular and Molecular Immunology of the Lung, First Medical Clinic, University of Mainz, Mainz, Germany. 2Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany. 3Respiratory Pharmacology Department, Aventis Pharmaceuticals, Bridgewater, New Jersey, USA. 4Department of Pathology and 5Institute of Immunology, University of Mainz, Mainz, Germany. 6Institute of Biochemistry, University of Kiel, Kiel, Germany. 7Department of Clinical Chemistry and Molecular Diagnostics, University of Marburg, Marburg, Germany. 8FACS Core Facility, Department of Toxicology, University of Mainz, Mainz, Germany. 9Department of Host Defence, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. 10Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. 11Laboratory of Immunology, First Medical Clinic, University of Mainz, Mainz, Germany.
H.A. Lehr’s present address is: Institute Universitaire de Pathologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland(Aysefa Doganci, Tatjana E)
Citation for this corrigendum: J. Clin. Invest. 115:1388 (2005). doi:10.1172/JCI200522433C1
Aysefa Doganci,1 Tatjana Eigenbrod,1 Norbert Krug,2 George T. De Sanctis,3 Michael Hausding,1 Veit J. Erpenbeck,2 El-Bdaoui Haddad,2 Hans A. Lehr,4 Edgar Schmitt,5 Tobias Bopp,5 Karl-J. Kallen,6 Udo Herz,7 Steffen Schmitt,8 Cornelia Luft,1 Olaf Hecht,2 Jens M. Hohlfeld,2 Hiroaki Ito,9 Norihiro Nishimoto,9 Kazuyuki Yoshizaki,10 Tadamitsu Kishimoto,10 Stefan Rose-John,6 Harald Renz,7 Markus F. Neurath,11 Peter R. Galle,11 and Susetta Finotto1
1Laboratory of Cellular and Molecular Immunology of the Lung, First Medical Clinic, University of Mainz, Mainz, Germany. 2Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany. 3Respiratory Pharmacology Department, Aventis Pharmaceuticals, Bridgewater, New Jersey, USA. 4Department of Pathology and 5Institute of Immunology, University of Mainz, Mainz, Germany. 6Institute of Biochemistry, University of Kiel, Kiel, Germany. 7Department of Clinical Chemistry and Molecular Diagnostics, University of Marburg, Marburg, Germany. 8FACS Core Facility, Department of Toxicology, University of Mainz, Mainz, Germany. 9Department of Host Defence, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. 10Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. 11Laboratory of Immunology, First Medical Clinic, University of Mainz, Mainz, Germany.
H.A. Lehr’s present address is: Institute Universitaire de Pathologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland(Aysefa Doganci, Tatjana E)